Analysts Conflictied on These Healthcare Names: Biogen Inc (NASDAQ: BIIB) and Cerecor Inc. (NASDAQ: CERC)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen Inc (NASDAQ: BIIB) and Cerecor Inc. (NASDAQ: CERC).

Biogen Inc (NASDAQ: BIIB)

Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen Inc (NASDAQ: BIIB) yesterday and set a price target of $290. The company’s shares closed yesterday at $294.07.

According to TipRanks.com, Syed is a 2-star analyst with an average return of 4.6% and a 66.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Amgen Inc., and Celgene.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $349, representing a 18.7% upside.

In a report issued on November 23, BMO Capital also maintained a Hold rating on the stock with a $294 price target.
Cerecor Inc. (NASDAQ: CERC)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cerecor Inc. (NASDAQ: CERC) yesterday and set a price target of $4. The company’s shares closed yesterday at $2.08, close to its 52-week low of $1.90.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.6% and a 32.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and HTG Molecular Diagnostics.

Cerecor Inc. has an analyst consensus of Moderate Buy.